Kanıt: Klinik çalışmalarda ZYTIGA



Similar documents
Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG study results presented at ASCO 2004

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

What s new in prostate cancer research? Highlights of GU-ASCO 2014

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment

First-line Hormone Therapy

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Background. t 1/2 of days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

Second line. Elena Verzoni Oncologia Medica Fondazione IRCCS Istituto Nazionale Tumori Milano

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice

Prostate Cancer Studies

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Clinical Spotlight in Breast Cancer

7. Prostate cancer in PSA relapse

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute

Historical Basis for Concern

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Management of low grade glioma s: update on recent trials

Cancer Treatments Subcommittee of PTAC Meeting held 18 September (minutes for web publishing)

Treatment of metastatic prostate cancer CLARE GILSON, THUBEENA MANICKAVASAGAR AND SIMON CHOWDHURY

Avastin in Metastatic Breast Cancer

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.

Advances in Prostate Cancer (Localized to Newly metastatic) Christopher Sweeney, MBBS Dana Farber Cancer Institute

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

DECISION AND SUMMARY OF RATIONALE

New Treatment Options for Breast Cancer

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Current management of advanced and castration resistant prostate cancer Leonard G. Gomella, MD, 1 Daniel P. Petrylak, MD, 2 Bobby Shayegan, MD 3 1

Breast Cancer Treatment Guidelines

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Prostate Cancer Treatment: What s Best for You?

REVIEW. Introduction. Key Words: prostatic cancer, biochemical recurrence, salvage radiotherapy, androgen deprivation therapy, systemic therapy

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Us TOO University Presents: Understanding Diagnostic Testing

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Does my patient need more therapy after prostate cancer surgery?

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

A new score predicting the survival of patients with spinal cord compression from myeloma

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

SRO Tutorial: Prostate Cancer Treatment Options

Avastin in breast cancer: Summary of clinical data

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Avastin in breast cancer: Summary of clinical data

2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Lung cancer is not just one disease. There are two main types of lung cancer:

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Activity of pemetrexed in thoracic malignancies

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

Transcription:

mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya

Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen Receptor inhibitors: -Bicalutamide -MDV 31 -ODM-21 -ARN 59 Castration (alhrh or Surg.) Testosterone Autocrine secretion Abiraterone Orteronel DNA Cell division

b Abiraterone: CYP17 blockade inhibits androgen synthesis

COU-AA-31: Abiraterone acetate Phase III post-chemotherapy 1195 patients with progressive mcrpc Failed 1 or 2 chemotherapy regimens, 1 of which contained docetaxel R A N D O M I Z E D 2:1 Abiraterone 1mg daily Prednisone 5mg BID n=797 Placebo daily Prednisone 5mg BID n=398 Efficacy end points (ITT) Primary end point: OS (25% improvement; HR.8) Secondary end points: TTPP rpfs PSA response FACT-P questionnaire Prospective data collection: Day 1 of Cycles 1, 4, 7, 1, and every 6 cycles thereafter until the end of study treatment Stratification by: ECOG performance status -1 vs 2 Worst pain over previous 24 hours BPI short form; -3 (absent) vs 4-1 (present) Prior chemotherapy 1 vs 2 Type of progression PSA only vs radiographic with or without PSA BPI, Brief Pain Inventory; HR, hazard ratio; ITT, intent to treat; TTPP, time to PSA progression; rpfs, radiographic progression-free survival; PSA, prostate-specific antigen Fizazi et al. Lancet Oncology 212 3(1):983-92 Harland et al. Eur J Cancer 213 Aug 22. pii: S959-849(13)72-X. doi: 1.116/j.ejca.213.7.144. [Epub ahead of print]

COU-AA-31 Baseline Demographics Abiraterone (n=797) Placebo (n=398) Total (n=1195) Median age, years (range) 69. (42-95) 69. (39-9) 69. (39-95) Race, % White 93.3 92.7 93.1 Black 3.5 3.8 3.6 Asian 1.4 2.3 1.7 ECOG PS 2, % 1.7 11.1 1.8 Significant pain present, % 44.3 44. 44.2 2 Prior chemotherapies, % 28.2 28.4 28.3

Extent of disease Baseline Disease Characteristics Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) Bone 89% 9% Node 45% 41% Liver 11% 8% Lung 13% 11% Other Visceral 6% 5% Prostate mass 8% 6% Other tissue 5% 5% Viscera, NOS.1% PSA (median, ng/ml) 128.8 (.4-9253) 137.7 (.6-1114) Hemoglobin (median, g/dl) 11.8 11.8 LDH (median, IU/L) 223. 237.5 de Bono et al. N Engl J Med 211; 346(21): 1995-25 de Bono et al. N Engl J Med 211; 346(21): 1995-25 (Supplementary Data)

Baseline Disease Characteristics Gleason score at initial diagnosis Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) 7 48.9% 46.% 8 51.1% 54.% PSA at initial diagnosis (ng/ml) Median (range) 27 (.1-1665.9) 35.5 (1.1-7378.) Previous cancer therapy Surgery 54% 49% Radiotherapy 72% 72% Hormonal 1% 1% Other* 1% 1% * Includes chemotherapy de Bono et al. N Engl J Med 211; 346(21): 1995-25 de Bono et al. N Engl J Med 211; 346(21): 1995-25 (Supplementary Data)

Survival Benefit Observed With AA Is Consistent For Majority of Subgroups Fizazi et al, abstr #7, ECCO 211

Survival (%) Survival (%) Survival by Baseline ECOG Status Favors AA for ECOG -1, but not for ECOG 2; May be Attributed by the Small Sample Size ECOG -1 ECOG 2 (1% of patients) 1 1 8 Abiraterone + prednisone: 17 months 8 Abiraterone + prednisone: 7.3 months 6 6 4 2 Placebo + Prednisone: 12.3 months 4 2 Placebo + prednisone: 7 months 6 12 18 24 3 6 12 18 24 3 Time to Death (Months) Time to Death (Months) 715 353 68 281 452 174 263 97 14 6 82 45 49 25 21 9 1 3 1 Median OS Abiraterone + prednisone vs. Placebo + prednisone ECOG -1: 17 vs. 12.3 months (HR=.74; 95% CI:.63-.87; p=.2) ECOG 2: 7.3 vs. 7 months (HR=.77; 95% CI:.5-1.17; p=.2166) Fizazi et al. Lancet Oncol 212; 13(1): 983-992 (Supplementary Appendix)

Survival (%) Survival (%) Survival (%) Survival Benefit Observed With AA Across All Age Groups < 65 Years 65 Years 75 Years 1 1 1 8 6 Abiraterone + prednisone : 15. months 8 6 Abiraterone + prednisone : 16.2 months 8 6 Abiraterone + prednisone : 15.6 months 4 2 Placebo + prednisone : 11.2 months 4 2 Placebo + prednisone : 11.1 months 4 2 Placebo + prednisone : 9.3 months 6 12 18 24 3 6 12 18 24 3 6 12 18 24 3 232 119 Time to Death (Months) 183 88 137 55 75 2 565 Time to Death (Months) 474 336 Median 22 OS Abiraterone 278 218 + prednisone 128 78 vs. Placebo 6 + prednisone: 111 82 < 65 years: 15. vs. 11.2 months (HR=.69; 95% CI:.53-.91) 65 years: 16.2 vs. 11.1 months (HR=.76; 95% CI:.63-.9) 75 years: 15.6 vs. 9.3 months (HR=.64; 95% CI:.48-.85) 198 13 22 Time to Death (Months) 18 131 44 76 27 6 4 Fizazi et al. ECCO 211: Abstract 7 (oral presentation)

Survival (%) Survival (%) Survival Benefit Observed With AA for Subgroups With and Without Visceral Disease at Study Entry Without Visceral Disease With Visceral Disease 1 1 8 Abiraterone + prednisone : 17.1 months 8 Abiraterone + prednisone : 12.9 months 6 6 4 2 Placebo + prednisone : 12.3 months 4 2 Placebo + prednisone : 8.3 months 6 12 18 24 544 299 466 242 Time to Death (Months) 345 146 22 78 15 5 3 Median OS Abiraterone + prednisone vs. Placebo + prednisone: Without visceral disease: 17.1 vs. 12.3 months (HR =.69; 95% CI:.58-.82) With visceral disease: 12.9 vs. 8.3 months (HR =.79; 95% CI:.59-1.5) 6 12 18 24 253 99 191 64 Time to Death (Months) 128 37 Fizazi et al. ECCO 211: Abstract 7 (oral presentation) 71 22 1 3

All Secondary End Points Achieved Statistical Significance Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) HR 95% CI TTPP (months) 1.2 6.6.58 (.46,.73) rpfs (months) 5.6 3.6.67 (.58,.78) P Value <.1 <.1 PSA response rate Total 38.% 1.1% - <.1 Confirmed 29.1% 5.5% - <.1 Objective response (RECIST) 14.% 2.8% - <.1 de Bono et al. N Engl J Med 211; 346(21): 1995-25

PSA Response Rate (%) Fizazi et al. ECCO 211: Abstract 7 (oral presentation) Fizazi et al. Lancet Oncol 212; 13(1): 983-992 Total and Confirmed PSA Response Rates Were Significantly Higher With AA 45 4 35 3 38.5 29.5 p <.1 p <.1 Total Confirmed 25 2 15 1 5 1.1 5.5 Abiraterone + prednisone Placebo + prednisone

COU-AA-31: Similar AE incidence rates were observed in both groups* Abiraterone + Prednisone (n=791) All Grades Grades 3/4 Placebo + Prednisone (n=394) All Grades Grades 3/4 All AEs 99% 6% 99% 61% Serious AEs 42% 36% 44% 38% AEs leading to discontinuation 21% 11% 24% 14% AEs leading to death 13% 16% *Grade 1 or 2 urinary tract infections were higher with abiraterone compared with placebo: 12% vs 7%, p=.2 AE, adverse event. Fizazi et al. Lancet Oncology 212 3(1):983-92 de Bono et al. New Eng J Med 211; 364: 1995-25

COU-AA-31: AEs of special interest Fluid retention and edema Abiraterone + Prednisone (n=791) All Grades Grade 3 Grade 4 Placebo + Prednisone (n=394) All Grades Grade 3 Grade 4 31% 2% <1% 22% 1% Hypokalemia 17% 3% <1% 8% 1% Cardiac disorders 13% 3% 1% 11% 2% <1% LFT abnormalities 1% 3% <1% 8% 3% <1% Hypertension 1% 1% 8% <1% Fizazi et al. Lancet Oncology 212 3(1):983-92 de Bono et al. New Eng J Med 211; 364: 1995-25

Gleason skoru prediktif değil Abiraterone ile klinik yararlanım Gleason skorundan bağımsız

Pain Intensity Abiraterone + Prednisone (n=797) Placebo + Prednisone (n=398) P Value HR (95% CI) Palliation rate 45% (157/349) 28.8% (47/163).5 - Time to palliation (median) Time to progression (25 th percentile) 5.6 months 13.7 months.18 7.4 months 4.7 months.88 1.675 (1.119 2.341).717 (.557-.922) Duration of palliation (median) 4.2 months 2.1 months.56 - Logothetis et al. Lancet Oncol 212: 212; 13: 121 17

Symptomatic Improvement Pain Interference AA (n = 797) Placebo (n = 398) P Value Palliation, n (%) 132/223 (59.2) 38/1 (38.).4 Time to palliation (months) Median (95% CI) 1.2 (.92-1.91) 3.71 (2.69-4.44).9 Time to progression (months) 25 th percentile (95% CI) 9.27 (7.39-12.88) 4.57 (2.79-6.47).19

Overall survival Outcomes AA (n = 797) Placebo (n = 398) P Value Median, months 14.8 1.9 <.1 PSA response rate Total 38.% 1.1% <.1 Confirmed 29.1% 5.5% <.1 Radiographic PFS Median, months 5.6 3.6 <.1 Time to first SRE (pathologic fracture/spinal cord compression/ palliative radiation/bone surgery) 25 th percentile, days 31. 15. <.1 Logothetis et al Lancet Oncol 211

Patients With Improvement (%) 7 6 5 4 3 2 1 AA Was Associated With Higher FACT-P Responses Abiraterone + prednisone (n = 797) * * p =.284 Placebo + prednisone (n = 398) * * * * p <.1 p <.5 48 32 46 28 54 48 54 39 44 33 41 28 58 4 46 25 Harland et al. ECCO 211: Abstract 71 (oral presentation)

Median time to decline (days) AA Delayed Time to Deterioration of QoL Abiraterone + prednisone (n=797) Placebo + prednisone (n=398) 45 4 35 * * * * * * p<.1 * 3 25 2 P=.325 * 15 1 5 363 253 339 24 168 89 424 226 337 169 424 274 262 142 395 253 Harland et al. ECCO 211: Abstract 71 (oral presentation)

COU-AA-31 Conclusions Abiraterone acetate prolonged OS in patients with mcrpc who have progressed after docetaxel-based chemotherapy Median OS improvement of approximately 5 months 36% improvement in median survival 35% risk reduction of death (HR =.65) Improved TTPP, PFS, and PSA response rate 38% of patients had a >5% reduction in PSA Clinical benefit for treatment of bone metastases: Improved pain palliation Delayed pain progression and time to SRE Effect sustained over treatment cycles Favorable Safety Profile

Tumor volume & activity Prostate cancer drug development Chemotherapy NOTE: This diagram represents typical disease progression. Some patients are metastatic at diagnosis and are thus still castrate Castration sensitive. Abiraterone Acetate Sipeuleucel-T Docetaxel Abiraterone Acetate Cabazitaxel Alpharadin Enzalutamide